Clinical Trial Update: Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing a lopinavir/ritonavir plus emtricitabine/tenofovir disoproxil fumarate regimen versus a lopinavir/ritonavir plus raltegravir regimen in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Emtricitabine/Tenofovir disoproxil fumarate (emtricitabine/tenofovir disoproxil fumarate)
• Lopinavir/ritonavir (lopinavir/ritonavir)
• Raltegravir (raltegravir)

Snippet

Sponsor: Abbott | Conditions: Human Immunodeficiency Virus Infection | Phase 3 | Status: COMPLETED | Results posted: 2011-02-02